AlphAIAlphAI — Financial news for AI agents
investing.comOCT 301 min read$ASPE

Aspen Neuroscience prices IPO at $15 per share

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, offering 9.375 million shares for gross proceeds of $140.6 million. The biotech company focuses on Parkinson's disease treatments. Shares began trading on Nasdaq under ASPE. Underwriters have a 30-day option for additional shares. The offering is expected to close November 2, 2026.

Original reporting
investing.com
Published Oct 30, 2026, 2:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$ASPE
Bullish
high confidence
Mentioned
$ASPE
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASPEBullishHigh
01

Why it matters

The IPO provides the company with capital to advance its lead candidate, sasineprocel, and adds a new tradable security for biotech investors.

02

Market read

First‑day pricing of a $140 M biotech IPO creates immediate trading interest and adds a new ticker to the Nasdaq biotech universe.

03

What to watch

No disclosed partners or revenue; reliance on future trial outcomes introduces execution risk

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Aspen Neuroscience is a clinical‑stage company developing iPSC‑derived cell therapies for Parkinson’s disease.

Company-level read

Ticker impact

$ASPEBullishHigh confidence
Context

Aspen Neuroscience priced its IPO at $15 per share, raising about $140.6 million and will begin trading today.

Expected impact

likely upward pressure as investors buy into the fresh offering

Evidence & confidence

First‑day trading often sees demand for newly listed, cash‑rich biotech; the $140 M raise signals strong financing.

Market effects

Sector

adds a new listed player to the clinical‑stage biotech space, may boost sector interest in iPSC therapies

Regional

U.S. biotech IPO pipeline gains another entrant, modest effect on Nasdaq biotech indices

Global

limited to investors tracking biotech IPOs and capital‑raising trends

Counterpoint

What could challenge this read

IPO pricing may be aggressive; post‑IPO lock‑up releases could pressure the stock downward

Key entities

  • company
    Aspen Neuroscience, Inc.

    Biotech firm launching its IPO on Nasdaq

  • underwriters
    Leerink Partners, Piper Sandler, Stifel, UBS, Oppenheimer

    Joint bookrunners for the offering

Read at source← All news

StoryAspen Neuroscience prices Parkinson’s cell-therapy IPO

Also covered by

6 outlets

Related articles

OCT 30
$ASPEHighAI 9/10

Aspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s

Aspen Neuroscience raised $140.6M in its IPO, selling 9.4M shares at $15 each. The company's cell therapy, sasineprocel, aims to treat Parkinson's by replenishing dopamine-producing neurons. It will trade under 'ASPE'. Early trial data showed potential improvements and a favorable safety profile. Long-term data is expected in 2028, with a Phase 3 study planned by the end of 2024. Aspen claims its personalized approach could be safer and more effective than donor-derived therapies.

finance.yahoo.com2 min
OCT 30
$ASPEHighAI 8/10

A Parkinson’s cell-therapy company expects about $140.6 million from its share sale, before costs.

Aspen Neuroscience, Inc. (Nasdaq: ASPE) announced its initial public offering of 9,375,000 shares at $14.95 per share, expected to raise $140.6 million before costs. Trading is set to begin on October 30, 2026, under the ticker ASPE. The offering is expected to close on November 2, 2026. The company focuses on developing autologous cell therapies for Parkinson's disease.

stocktitan.net2 min